Sorafenib, in combination with conventional transarterial chemoembolization (cTACE), does not significantly improve overall survival (OS) in hepatocellular carcinoma (HCC) patients, relative to sorafenib alone, a recent study has found.
Taking curcumin daily in addition to losing weight does not exert a superior effect on cardiovascular (CV) risk factors in patients with nonalcoholic fatty liver disease (NAFLD) when compared with losing weight alone, according to a study.
Women with a high body mass index (BMI) early in life are at heightened risk of developing severe liver disease later in life, and obesity is associated with the greatest risk, as reported in a recent study.
Mycophenolate mofetil is well tolerated and highly effective in the second-line treatment of patients with autoimmune hepatitis (AIH), although response is greater in those who initiated treatment due to intolerance to standard therapy than in those with nonresponse, according to a systematic review and meta-analysis.
Use of pegbelfermin, a PEGylated human fibroblast growth factor 21 analogue, in the treatment of patients with nonalcoholic steatohepatitis leads to a substantial reduction in hepatic fat fraction and is generally well tolerated, according to the results of a phase IIa trial.